APA (7th ed.) Citation

Lui, A., Vanleuven, J., Perekopskiy, D., Liu, D., Xu, D., Alzayat, O., . . . Liu, D. (2022). FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders. Pharmaceuticals (14248247), 15(12), 1546. https://doi.org/10.3390/ph15121546

Chicago Style (17th ed.) Citation

Lui, Austin, et al. "FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders." Pharmaceuticals (14248247) 15, no. 12 (2022): 1546. https://doi.org/10.3390/ph15121546.

MLA (9th ed.) Citation

Lui, Austin, et al. "FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders." Pharmaceuticals (14248247), vol. 15, no. 12, 2022, p. 1546, https://doi.org/10.3390/ph15121546.